Providence Cancer Center, Earle A. Chiles Research Institute, University of Portland, The Oregon Clinic
College of Arts & Sciences
Department of Biology
Hormone receptor positive (HR+) breast cancer patients have an excellent prognosis with over 85% cure rates. However, 20,000 women with HR+ breast cancer die annually from tumor recurrence. Those at highest risk for recurrence are those women whose tumors continue to proliferate through estrogen blockade (Figure 4). Addition of chemotherapy for these patients failed to improve outcomes. We retrospectively identified women with HR+ breast cancer treated neoadjuvantly with aromatase inhibitors (AI), and selected matched patient cohorts for responders and non-responders determined by post-AI Ki67 of
Breast--Cancer--Research; Breast--Cancer--Treatment; Oncology
Citation: Pilot Scholars Version (Modified MLA Style)
Hayashi, Jeffrey; Yamazaki, Tomoko; Rajamanickam, Venkatesh; Pucilowska, Joanna; Dubay, Christopher; Page, David; and Young, Kristina, "Expression in Aromatase Inhibitor Responder vs. Non-Responder HR+ Breast Cancer Cohorts" (2018). Biology Undergraduate Publications, Presentations and Projects. 10.